Welcome to our dedicated page for Nordea Bk Abp Med Term Nts news (Ticker: NRDBY), a resource for investors and traders seeking the latest updates and insights on Nordea Bk Abp Med Term Nts stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nordea Bk Abp Med Term Nts's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nordea Bk Abp Med Term Nts's position in the market.
Nordea Bank Abp (OTC:NBNKF) disclosed a managers' transaction: Mark Kandborg, member of the Nordea Group Leadership Team, received 9,123 shares as a share-based incentive.
The transaction date was 19 March 2026, reported under the EU Market Abuse Regulation and published on 20 March 2026 at 16.00 EET. ISIN: FI4000297767. Unit price recorded: 0 DKK.
Nordea Bank Abp (NBNKF) reports that Leadership Team member Nina Arkilahti received 26,289 shares on 19 March 2026 under a share-based incentive, as notified under the EU Market Abuse Regulation.
The transaction was an initial notification, recorded with zero unit price for regulatory disclosure purposes.